{"id":"W1982234365","doi":"10.1007/s10549-013-2814-5","title":"Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2","year":2013,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Exemestane; Everolimus; Medicine; Hazard ratio; Breast cancer; Aromatase inhibitor; Internal medicine; Oncology; Clinical endpoint; Cancer; Discontinuation; Randomized controlled trial; Aromatase; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002437991,0.0005544001,0.0008547506,0.0005607702,0.0001864792,0.00007703256,0.0002076359,0.0001722094,0.002698421],"category_scores_gemma":[0.0000132072,0.0004195812,0.000103894,0.001010587,0.0004000735,0.0004582889,0.0001013674,0.0005294255,0.00008859225],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003758545,"about_ca_system_score_gemma":0.001031024,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.07359025,"about_ca_topic_score_gemma":0.01956423,"domain_scores_codex":[0.9960511,0.0001369965,0.0005227815,0.0009925616,0.0008387579,0.001457849],"domain_scores_gemma":[0.9980678,0.0001513898,0.0001019213,0.0006216341,0.0004464838,0.0006108033],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01259774,0.001423448,0.1263303,0.0001007444,0.0002642671,0.0003860451,0.001100247,0.0004191452,0.002371127,0.00006846062,0.00006158234,0.8548769],"study_design_scores_gemma":[0.02948952,0.002196837,0.9574912,0.00118342,0.00002518767,0.000760184,0.0007722119,0.0003588604,0.001544249,0.001040499,0.004639955,0.0004978422],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9582352,0.01712303,0.000005770353,0.0207519,0.0001205388,0.002926492,0.0003195699,0.00007970315,0.0004377954],"genre_scores_gemma":[0.9519284,0.03932281,0.0001202864,0.0003652397,0.0003159628,0.005701724,0.00003082224,0.0001030659,0.002111685],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.854379,"threshold_uncertainty_score":0.9998256,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04306472712332436,"score_gpt":0.3792331120347472,"score_spread":0.3361683849114229,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}